Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment

This publication has 11 references indexed in Scilit:

• Targeted delivery of antisense oligonucleotides in cancer
  Journal of Controlled Release, 2001
• Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line
  Cancer Gene Therapy, 2001
• Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects
  JNCI Journal of the National Cancer Institute, 2000
• Molecular Biology of Neuroblastoma
  Journal of Clinical Oncology, 1999
• Correlation of Toxicity and Pharmacokinetic Properties of a Phosphorothioate Oligonucleotide Designed to Inhibit ICAM-1
  Toxicologic Pathology, 1999
• Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.
  Journal of Clinical Oncology, 1998
• Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol.
  Proceedings of the National Academy of Sciences, 1995
• Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?
  Science, 1993
• Therapeutic Applications of Oligonucleotides
  Annual Review of Pharmacology and Toxicology, 1992
• Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma.
  Proceedings of the National Academy of Sciences, 1984